We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development
Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development
September 18, 2012
Merck KGaA has withdrawn its EU marketing application for a lung cancer indication for its cancer drug Erbitux after regulatory authorities requested more clinical data.